CoChat

GLP-1 receptor agonists for Parkinson's disease

Open access
Mulvaney, Caroline A, Duarte, Gonçalo S, Handley, Joel, Evans, David JW, Menon, Suresh, Wyse, Richard, Emsley, Hedley CA · 2020 · Cochrane Database of Systematic Reviews
Cited by 69

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain. Insulin signalling in the brain plays a key role in neuronal metabolism and repair and in synaptic efficacy, but insulin signalling is desensitised in the brain of people with PD. Researchers are exploring the neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders such as PD. OBJECTIVES: To evaluate the effectiveness and safety of GLP-1 receptor agonists for Parkinson's disease. SEARCH METHODS: We searched the Cochrane Movement Disorders Group trials register; the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library; and Ovid MEDLINE and Embase. We also searched clinical trials registries, and we handsearched conference abstracts. The most recent search was run on 25 June 2020. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of adults with PD that compared GLP-1 receptor agonists with conventional PD treatment, placebo, or no treatment. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We rated the quality of evidence using GRADE. We resolved discrepancies between the two data extractors by consultation with a third review author. MAIN RESULTS: Through our searches, we retrieved 99 unique records, of which two met our inclusion criteria. One double-blind study of exenatide versus placebo randomised 62 participants, who self-administered exenatide or placebo for 48 weeks and were followed up at 60 weeks after a 12-week washout. One single-blind study of exenatide versus no additional treatment randomised 45 participants; participants in the intervention group self-administered exenatide for 12 months, and all participants were followed up at 14 months and 24 months following absence of exenatide for 2 months and 12 months, respectively. These trials had low risk of bias, except risk of performance bias was high for Aviles-Olmos 2013. Exenatide versus placebo Primary outcomes We found low-certainty evidence suggesting that exenatide improves motor impairment as assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III in the off-medication state (mean difference (MD) -3.10, 95% confidence interval (CI) -6.11 to -0.09). The difference in scores was slightly greater when scores were adjusted for baseline severity of the condition (as reported by study authors) (MD -3.5, 95% CI -6.7 to -0.3), exceeding the minimum clinically important difference (MCID). We found low-certainty evidence suggesting that exenatide has little or no effect on health-related quality of life (HRQoL) as assessed by the Parkinson's Disease Questionnaire (PDQ)-39 Summary Index (SI) (MD -1.80, 95% CI -6.95 to 3.35), the EuroQol scale measuring health status in five dimensions (EQ5D) (MD 0.07, 95% CI -0.03 to 0.16), or the EQ5D visual analogue scale (VAS) (MD 5.00, 95% CI -3.42 to 13.42). Eight serious adverse events (SAEs) were recorded, but all were considered unrelated to the intervention. Low-certainty evidence suggests that exenatide has little or no effect on weight loss (risk ratio (RR) 1.25, 95% CI 0.89 to 1.76). Exenatide versus no treatment Primary outcomes at 14 months We found very low-certainty evidence suggesting that exenatide improves motor impairment as assessed by MDS-UPDRS Part III off medication (MD -4.50, 95% CI -8.64 to -0.36), exceeding the MCID. We are uncertain whether exenatide improves HRQoL as assessed by the PDQ-39 SI (MD 3.50, 95% CI -2.75 to 9.75; very low-quality evidence). We found very low-certainty evidence suggesting that exenatide has little or no effect on the number of SAEs (RR 1.60, 95% 0.40 to 6.32). We found very low-certainty evidence suggesting that exenatide may lead to weight loss (MD -2.40 kg, 95% CI -4.56 to -0.24). Primary outcomes at 24 months We found evidence as reported by study authors to suggest that exenatide improves motor impairment as measured by MDS-UPDRS Part III off medication (MD 5.6 points, 95% CI 2.2 to 9.0). Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). AUTHORS' CONCLUSIONS: Low- or very low-certainty evidence suggests that exenatide may improve motor impairment for people with PD. The difference in motor impairment observed between groups may persist for some time following cessation of exenatide. This raises the possibility that exenatide may have a disease-modifying effect. SAEs were unlikely to be related to treatment. The effectiveness of exenatide for improving HRQoL, non-motor outcomes, ADLs, and psychological outcomes is unclear. O

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd012990.pub2

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 58

  1. Athauda D Budnik N Chowdhury K Skene S Foltynie T The effect of exenatide on specific non-motor symptoms in Parkinson’s disease – a post-hoc analysis European Journal of Neurology Issue S2 edition Abstracts of the 4th Congress of the European Academy of Neurology, Lisbon, Portugal, June 2018 2018 309 · DOI · Paper page
  2. Athauda, 2019, Post hoc analysis of the exenatide-PD trial - factors that predict response, European Journal of Neuroscience, 49, 410, 10.1111/ejn.14096 · DOI · Paper page
  3. Athauda, 2018, What effects might exenatide have on non-motor symptoms in Parkinson's disease: a post hoc analysis, Journal of Parkinson’s Disease, 8, 247, 10.3233/JPD-181329 · DOI · Paper page
  4. Athauda, 2017, Is exenatide a treatment for Parkinson's disease?, Journal of Parkinson's Disease, 7, 451, 10.3233/JPD-171192 · DOI
  5. Aviles-Olmos, 2015, Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease, Journal of Parkinson's Disease, 4, 337, 10.3233/JPD-140364 · DOI · Paper page
  6. Aviles-Olmos, 2012, An open label, single site, 12 month, phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (exenatide) in the treatment of patients with moderate severity Parkinson's disease [abstract], Movement Disorders, 27
  7. Foltynie, 2014, Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic, Alzheimer's and Dementia, 10, S38, 10.1016/j.jalz.2013.12.005 · DOI · Paper page
  8. Al-Bachari, 2017, Structural and physiological neurovascular changes in idiopathic Parkinson’s disease and its clinical phenotype, Journal of Cerebal Blood Flow & Metabolism, 37, 3409, 10.1177/0271678X16688919 · DOI · Paper page
  9. Ascherio, 2016, The epidemiology of Parkinson’s disease: risk factors and prevention, Lancet Neurology, 15, 1257, 10.1016/S1474-4422(16)30230-7 · DOI · Paper page
  10. Aviles-Olmos, 2013, Parkinson's disease, insulin resistance and novel agents of neuroprotection, Brain, 136, 374, 10.1093/brain/aws009 · DOI · Paper page
  11. Aviles-Olmos, 2013, Exenatide and the treatment of patients with Parkinson's disease, Journal of Clinical Investigation, 123, 2730, 10.1172/JCI68295 · DOI · Paper page
  12. Aviles-Olmos, 2014, Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease, Journal of Parkinson's Disease, 4, 337, 10.3233/JPD-140364 · DOI · Paper page
  13. Bomfim, 2012, An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A-beta oligomers, Journal of Clinical Investigation, 122, 1339, 10.1172/JCI57256 · DOI · Paper page
  14. Chaudhuri, 2008, Quantitation of nonmotor symptoms in Parkinson's disease, European Journal of Neurology, 15 Suppl 2, 2, 10.1111/j.1468-1331.2008.02212.x · DOI · Paper page
  15. Boer, 1996, Quality of life in patients with Parkinson's disease: development of a questionnaire, Journal of Neurology, Neurosurgery, and Psychiatry, 61, 70, 10.1136/jnnp.61.1.70 · DOI · Paper page
  16. Doyle, 2003, Pharmacological agents that directly modulate insulin secretion, Pharmacological Reviews, 55, 105, 10.1124/pr.55.1.7 · DOI · Paper page
  17. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  18. Erbila, 2019, GLP-1’s role in neuroprotection: a systematic review, Brain Injury, 33, 734, 10.1080/02699052.2019.1587000 · DOI · Paper page
  19. Fahn, 1987, Recent Developments in Parkinson’s Disease, 2, 153
  20. Freiherr, 2013, Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence, CNS Drugs, 27, 505, 10.1007/s40263-013-0076-8 · DOI · Paper page
  21. Ghasemi, 2013, Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders, Molecular Neurobiology, 47, 1045, 10.1007/s12035-013-8404-z · DOI
  22. Goetz, 2000, Objective changes in motor function during placebo treatment in PD, Neurology, 54, 710, 10.1212/wnl.54.3.710 · DOI · Paper page
  23. Goetz, 2008, The Unified Dyskinesia Rating Scale: presentation and clinimetric profile, Movement Disorders, 23, 2398, 10.1002/mds.22341 · DOI · Paper page
  24. Hammarlund, 2012, Measuring outcomes in Parkinson’s disease: a multi-perspective concept mapping study, Quality of Life Research, 21, 453, 10.1007/s11136-011-9995-3 · DOI
  25. Harkavyi, 2008, Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease, Journal of Neuroinflammation, 5, 11, 10.1186/1742-2094-5-19 · DOI · Paper page
  26. Hely, 2008, The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years, Movement Disorders, 23, 837, 10.1002/mds.21956 · DOI · Paper page
  27. Hirsch, 2016, The incidence of Parkinson’s disease:a systematic review and meta-analysis, Neuroepidemiology, 46, 292, 10.1159/000445751 · DOI · Paper page
  28. Hoehn, 1967, Parkinsonism: onset, progression, and mortality, Neurology, 17, 427, 10.1212/WNL.17.5.427 · DOI · Paper page
  29. Holst, 2004, Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors, Expert Opinion on Emerging Drugs, 9, 155, 10.1517/eoed.9.1.155.32952 · doi:10.1517/eoed.9.1.155.32952 · Paper page
  30. Horváth, 2015, Minimal clinically important difference on the Motor Examination part of MDS-UPDRS, Parkinsonism & Related Disorders, 21, 1421, 10.1016/j.parkreldis.2015.10.006 · DOI · Paper page
  31. Horváth, 2017, Changes in quality of life in Parkinson's disease: how large must they be to be relevant?, Neuroepidemiology, 48, 1, 10.1159/000455863 · DOI · Paper page
  32. Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases, Journal of Neurology, Neurosurgery, and Psychiatry, 55, 181, 10.4103/0972-2327.83083 · DOI
  33. Hölscher, 2014, Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases, Biochemical Society Transactions, 42, 593, 10.1042/BST20140016 · DOI · Paper page
  34. Hölscher, 2018, Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models, Neuropharmacology, 251, 10.1016/j.neuropharm.2018.01.040 · DOI · Paper page
  35. Jalewa, 2016, Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells, Journal of Neurochemistry, 139, 55, 10.1111/jnc.13736 · DOI · Paper page
  36. Jenkinson, 1997, The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire, Psychology and Health, 12, 805, 10.1002/mds.10678 · DOI
  37. Ji, 2016, Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease, Reviews in the Neurosciences, 27, 61, 10.1515/revneuro-2015-0021 · DOI · Paper page
  38. Kalia, 2015, Parkinson’s disease, Lancet, 386, 896, 10.1016/S0140-6736(14)61393-3 · DOI · Paper page
  39. Li, 2010, GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease, Journal of Alzheimer's Disease, 19, 1205, 10.3233/JAD-2010-1314 · DOI · Paper page
  40. Li, 2016, Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model, Neuropharmacology, 101, 255, 10.1016/j.neuropharm.2015.10.002 · DOI
  41. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700 · DOI · Paper page
  42. Liu, 2015, Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease, European Journal of Pharmacology, 765, 284, 10.1016/j.ejphar.2015.08.038 · DOI
  43. Long-Smith, 2013, The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease, Neuromolecular Medicine, 15, 102, 10.1007/s12017-012-8199-5 · DOI
  44. Malek, 2016, Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease, Movement Disorders, 31, 1518, 10.1002/mds.26698 · DOI · Paper page
  45. Mattis, 1976, Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians
  46. McGhee, 2013, A systematic review of biomarkers for disease progression in Parkinson’s disease, BMC Neurology, 13, 35, 10.1186/1471-2377-13-35 · DOI
  47. Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  48. Moroo, 1994, Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease, Acta Neuropathologica, 87, 343, 10.1007/BF00313602 · DOI · Paper page
  49. Morris, 2011, Insulin resistance impairs nigrostriatal dopamine function, Experimental Neurology, 231, 171, 10.1016/j.expneurol.2011.06.005 · DOI · Paper page
  50. Müller, 2000, Levodopa in plasma correlates with body weight of parkinsonian patients, Parkinsonism & Related Disorders, 6, 171, 10.1016/S1353-8020(00)00005-5 · doi:10.1016/s1353-8020(00)00005-5
  51. Pleuvry, 2004, Receptors, agonists and antagonists, Anaesthesia & Intensive Care Medicine, 5, 350, 10.1383/anes.5.10.350.52312 · doi:10.1383/anes.5.10.350.52312
  52. Review Manager 5 (RevMan 5) The Nordic Cochrane Centre, The Cochrane Collaboration 2014
  53. Schernhammer, 2011, Diabetes and the risk of developing Parkinson's disease in Denmark, Diabetes Care, 34, 1102, 10.2337/dc10-1333 · DOI · Paper page
  54. Schwab, 1969, Third Symposium on Parkinson’s Disease, 152
  55. Sun, 2012, Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications, Diabetes Care, 35, 1047, 10.2337/dc11-1511 · DOI · Paper page
  56. Wahlqvist, 2012, Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with type 2 diabetes in a Taiwanese population cohort, Parkinsonism & Related Disorders, 18, 753, 10.1016/j.parkreldis.2012.03.010 · DOI · Paper page
  57. Sherbourne, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Medical Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  58. Zhang, 2015, Neuroprotective effects of (Val8) GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model, Behavioural Brain Research, 293, 107, 10.1016/j.bbr.2015.07.021 · DOI

Cited by

See all 69

Metadata

Authors
Mulvaney, C. A., Duarte, G. S., Handley, J., Evans, D. J., Menon, S., Wyse, R., & Emsley, H. C.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2020-07-23
Volume
2020
Issue
7
Pages
CD012990-CD012990
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2794447083
Cited by
69
References
18
FWCI
3.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 receptor agonists for Parkinson's disease. https://app.cochat.ai/papers/10.1002/14651858.cd012990.pub2
The paper
Mulvaney, C. A., Duarte, G. S., Handley, J., Evans, D. J., Menon, S., Wyse, R., & Emsley, H. C. (2020). GLP-1 receptor agonists for Parkinson's disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd012990.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.